| Human immunodeficiency virus I infection
Edurant vs Juluca
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Edurant vs Juluca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJuluca has a higher rate of injection site reactions vs Edurant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Juluca but not Edurant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Edurant
Juluca
At A Glance
Oral
Once daily
Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Oral
Once daily
INSTI/NNRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 25 mg oral tablet once daily with a meal for patients weighing at least 25 kg. Pediatric patients 2 years and older weighing 14-20 kg receive 12.5 mg (5 x 2.5 mg dispersed tablets); 20-25 kg receive 15 mg (6 x 2.5 mg dispersed tablets). During pregnancy with virologic suppression, 25 mg once daily with a meal. When coadministered with rifabutin, increase to 50 mg (two 25 mg tablets) once daily with a meal.
Human immunodeficiency virus I infection One tablet (dolutegravir 50 mg/rilpivirine 25 mg) orally once daily with a meal; if coadministered with rifabutin, take an additional rilpivirine 25-mg tablet with JULUCA once daily with a meal for the duration of rifabutin coadministration.
Contraindications
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (more than single-dose treatment)
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
- Previous hypersensitivity reaction to dolutegravir or rilpivirine
- Coadministration with dofetilide
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with systemic dexamethasone (more than a single-dose treatment)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
Adverse Reactions
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, rash, dizziness, nausea, abdominal pain, vomiting, fatigue
Serious Skin and hypersensitivity reactions including DRESS, hepatotoxicity, depressive disorders
Postmarketing Nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Most common (>=2%) Diarrhea, headache, nausea
Serious Depressive disorders including suicidal ideation, hepatotoxicity, skin and hypersensitivity reactions
Postmarketing Acute liver failure, hepatotoxicity, weight increase, arthralgia, myalgia, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Pharmacology
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
JULUCA is a fixed-dose combination of dolutegravir, an integrase strand transfer inhibitor (INSTI) that blocks the strand transfer step of retroviral DNA integration essential for HIV replication, and rilpivirine, a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI) that non-competitively inhibits HIV-1 reverse transcriptase without inhibiting human cellular DNA polymerases alpha, beta, or gamma.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Edurant
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (11/12)
Juluca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (1/12) · Qty limit (11/12)
UnitedHealthcare
Edurant
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Juluca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Edurant
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Juluca
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EdurantView full Edurant profile
JulucaView full Juluca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.